Press Releases

Boston Scientific to Release Broad Range of Clinical Results on Endoscopic Technologies at DDW® 2006

Physicians offer preview of SpyGlass™ Direct Visualization System

PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)
May 18, 2006

NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at Digestive Disease Week® (DDW®), which runs from May 20 to 25 in Los Angeles. Boston Scientific will be announcing results from several clinical studies, aimed to determine the safety and effectiveness of leading endoscopic technologies including the Polyflex® Esophageal Stent and the Resolution® Clip. Physicians will also share results from the first human use clinical series and bench simulation study of Boston Scientific's SpyGlass™ Direct Visualization System.

"The data we present at DDW support the effectiveness of our leading endoscopic technologies in managing patients with esophageal and gastrointestinal diseases," said Michael P. Phalen, President, Boston Scientific Endoscopy. "Innovative treatment options, such as the Polyflex Esophageal Stent and Resolution Clip, aim to improve patients' quality of life through a less-invasive approach."

Schedule of Events (Partial Listing)

Please note that the data is embargoed until the beginning of each session.

  Sunday, May 21 (all times are PT)

  * Resolution Hemoclip for GI bleeding.
    The Company will announce results of a study to determine the efficacy
    of using the Resolution Clip, an endoscopic mechanical clip, to treat
    gastrointestinal (GI) bleeding instead of traditional electrocautery and
    injection therapy.  The poster presentation prepared by Mitchell Kaplan,
    M.D., and Sri Komanduri, M.D., M.S., titled "The Efficacy of the
    Resolution Hemoclip in Hemodynamically Significant Upper and Lower GI
    Bleeds: A Safe and Effective Alternative to Cautery" will be available
    from 8:00 a.m. - 5:00 p.m. in West Hall A of the Los Angeles Convention
    Center.

  * Polyflex Stent in RNBES.
    The Company will announce results of a study to determine the efficacy
    of using the Polyflex Esophageal Stent to reduce the number of dilations
    to relieve dysphagia caused by resilient non-peptic benign esophageal
    strictures (RNBES).  The poster presentation prepared by Rajesh
    Santharam, M.D., and Kulwinder S. Dua, M.D., titled "Continuous Non-
    Permanent Dilation of Resilient Non-Peptic Benign Esophageal Strictures
    Using a Self-Expanding Plastic Esophageal Stent (Polyflex®): A
    Prospective Study" will be available from 8:00 a.m. - 5:00 p.m. in West
    Hall A.

  Monday, May 22

  * SpyGlass™ Direct Visualization System.
    At 4:00 p.m., an oral presentation titled "Pilot Evaluation of a Direct
    Visualization Probe for Intraductal Examination of the Biliary System"
    will be presented by Soren Meisner, M.D. in Room 511 A/B.  Immediately
    following at 4:12 p.m., results from the first human-use clinical series
    and bench simulation study of the SpyGlass Direct Visualization System
    will be presented by Yang K. Chen, M.D., during an oral presentation
    titled "Results From the First Human Use Clinical Series Utilizing a New
    Peroral Cholangiopancreatoscopy System (SpyGlass Direct Visualization
    System)".

  Tuesday, May 23

  * Polyflex Stent in anastomotic strictures.
    The Company will announce results of a study, which examined the
    placement of the Polyflex Esophageal Stent to determine its efficacy in
    managing patients with persistent anastomotic strictures (AS).  The
    poster presentation prepared by James S. Barthel, M.D. et al., titled
    "Management of Persistent Gastroesophageal Anastomotic Strictures with
    Polyflex Stents: An Alternative to Serial Dilation" will be available
    from 8:00 a.m. - 5:00 p.m. in West Hall A.


  * Hemoclip study for coumadin therapy patients.
    At 3:15 p.m., the Company will announce results of a study designed to
    investigate the use of hemostatic clips in patients on coumadin®
    anticoagulation therapy (CAC) who undergo a colonoscopy.  The results
    will be presented by Douglas A. Howell, M.D., during an oral session
    titled "Use of Hemostatic Clips in Patients Undergoing Colonoscopy in
    the Setting of Coumadin Anticoagulation Therapy", in Room 511 A/B/C.

Boston Scientific will issue trade-specific press releases covering all of the studies mentioned in the Company's schedule of events.

Boston Scientific will present its latest innovations at booth #1227, including the next generation of the market-leading, single-use biopsy forceps -- Radial Jaw® 4. The Company will also offer hands-on product demonstration sessions of the RX Biliary System™, Resolution Clip, Radial Jaw 4 Biopsy Forceps, and the Polyflex Esophageal Stent in its Simulated Clinical Endoscopy Suite.

About Digestive Disease Week®

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the Society for Surgery of the Alimentary Tract, DDW takes place May 20 - 25, 2006, in Los Angeles. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.

  CONTACT:
  Milan Kofol
  508-650-8569
  Investor Relations
  Boston Scientific Corporation

  Paul Donovan
  508-650-8541
  Media Relations
  Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul
Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific
Corporation

Web site: http://www.bostonscientific.com/